The authors proposed that defactinib is an attractive molecule for repurposing to treat patients with UC or other inflammatory conditions, such as arthritis, acute lung injury, or atherosclerosis, in which IRF5 function in macrophages has been intimately linked to pathogenicity [34]. This evidence concerns the gene IRF5 and arthritic joint disease.